

**JEEVAN SCIENTIFIC TECHNOLOGY LIMITED**  
Registered Office: Plot No. 1 & 2, Sai Krupa Enclave, Manikonda Jagir, Near Lanco Hills, Hyderabad-500008.  
**CONSOLIDATED AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2021**

Rupees in Lakhs

Sl.No	Particulars	Quarter Ended			Year Ended
		30-06-2021 UnAudited	31-03-2021 Audited	30-06-2020 UnAudited	
1	<b>Income</b>				
	(a) Revenue From Operations	1620.37	1537.28	533.40	4787.59
	(b) Other Income	8.50	9.13	31.57	93.91
	(c) Unbilled Revenue	0.00	0.00	-33.80	53.00
	<b>Total Income</b>	<b>1,628.87</b>	<b>1,546.41</b>	<b>531.17</b>	<b>4,934.50</b>
2	<b>Expenses</b>				
	(a) Cost of Material Consumed	83.69	117.14	10.78	274.55
	(b) Purchase of stock-in-trade		-	-	-
	(c) Changes in Inventories of finished goods, work-in-progress and stock-in-trade	-14.79	-33.70	2.40	-210.30
	(d) Employee benefit expense	441.83	360.33	252.63	1253.34
	(e) Finance Cost	26.82	15.24	63.78	209.36
	(f) Depreciation and Amortisation expense	99.55	98.63	98.84	396.83
	(g) Other Expenses	521.65	605.76	188.86	1645.78
	<b>Total Expenses</b>	<b>1,158.75</b>	<b>1,163.40</b>	<b>617.29</b>	<b>3,569.56</b>
3	Profit before exceptional items and Tax	470.12	383.01	-86.12	1,364.94
4	Add(+)/Less(-) Exceptional Items		-	-	0.00
5	Profit/ (Loss) before Tax	470.12	383.01	-86.12	1,364.94
6	Tax Expenses	138.12	-1.22	28.31	190.94
7	Profit(Loss) for the Period from Continuing Operations	332.00	384.23	-57.81	1174.00
8	Profit(Loss) from Discontinuing Operations		-	-	-
9	Tax Expenses on discontinuing Operations		-	-	-

Sl.No	Particulars	Quarter Ended				Year Ended
		30-06-2021	31-03-2021	30-06-2020	31-03-2021	
10	Profit(Loss) from Discontinuing Operations after Tax	UnAudited	Audited	UnAudited	Audited	
11	Profit(Loss) for the period	332.00	384.23	-57.81	1,174.00	
12	Other Comprehensive Income					
	A (i) Items that will not be reclassified to profit or loss	0.63	6.80	0.51	5.96	
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	
13	Total Comprehensive Income for the period	332.63	391.03	-57.30	1,179.96	
14	Paid Up Equity Share Capital (Face Value of Rs.10/- each)	1,530.15	1,530.15	1,530.15	1,530.15	
15	Other equity excluding revaluation reserve				1972.12	
16	Earnings per Equity share ( for continuing operations)					
	a) Basic (Amount in Rupees)	2.17	2.56	-0.37	7.71	
	b) Diluted (Amount in Rupees)	2.17	2.56	-0.37	7.71	
17	Earnings per Equity share ( for discontinued operations)					
	a) Basic (Amount in Rupees)					
	b) Diluted (Amount in Rupees)					
18	Earnings per Equity share ( for Continuing & discontinued operations)					
	a) Basic (Amount in Rupees)	2.17	2.56	-0.37	7.71	
	b) Diluted (Amount in Rupees)	2.17	2.56	-0.37	7.71	

**Notes to the Consolidated Audited Financial Results**

- The above financial results are prepared in accordance with IND AS notified under the Company (Indian Accounting Standards) Rules, 2015
- The above results have been reviewed by the Audit Committee at its meeting held on 09.08.2021 and approved by the Board of Directors of the Company on the same date. These Results are also subjected to Limited Review by the Company's Statutory Auditors.
- The Group currently has two segments (i) clinical research services and (ii) Information technology services.
- The company has considered the possible effects that may result from the pandemic relating to Covid 19 on the carrying amounts of receivables, inventories, property, plant and equipment and intangible assets. In developing the assumptions relating to the future possible uncertainties in the global economic conditions, the Company has, at the date of approval of these standalone financial results, used internal and external sources of information, including economic forecasts and estimates from market sources, on the expected future performance of the company. On the basis of evaluation and current indicators of future economic conditions, the Company expects to recover the carrying amounts of the above assets and does not anticipate any impairment to these financial and non-financial assets. However, the impact assessment of Covid-19 is a continuing process, given the uncertainties
- Figures for the previous periods have been rearranged wherever necessary.
- The above consolidated financial results include the Audited financial results of the wholly owned subsidiaries, M/s Enhops Solutions Pvt Ltd & Enhops Inc.

for Jeevan Scientific Technology Limited  
On behalf of the Board of Directors

K. Krishna Kishore  
Vice Chairman & Managing Director

M.Srikanth Sasidhar  
CFO

Place:Hyderabad  
Date:09.08.2021



SEGMENT-WISE REVENUE, RESULTS & CAPITAL EMPLOYED (Consolidated Unaudited)  
UNDER CLAUSE 41 OF THE LISTING AGREEMENT FOR THE QUARTER ENDED 30TH JUNE, 2021

Particulars	Quarter Ended		Year Ended	
	30-06-2021	31-03-2021	30-06-2020	31-03-2021
<b>SEGMENT REVENUE: (Net Sales / Income from Operations)</b>	<b>UnAudited</b>	<b>Audited</b>	<b>UnAudited</b>	<b>Audited</b>
a) Clinical Research Services	1383.98	1,363.74	342.26	4,284.79
b) Information Technology Services	244.89	182.67	188.91	649.71
Total:	1,628.87	1,546.41	531.17	4,934.50
LESS: Inter Segment revenue				
Net Sales/Income from Operations:	1,628.87	1,546.41	531.17	4,934.50
<b>SEGMENT RESULTS : PROFIT / (LOSS) BEFORE TAX AND INTEREST</b>				
a) Clinical Research Services	452.00	361.47	-77.80	1,489.47
b) Information Technology Services	44.94	36.78	55.46	84.83
Total:	496.94	398.25	-22.34	1,574.30
LESS:				
i) Interest	26.82	15.24	63.78	209.36
ii) Other Un-Allocable Expenditure	-	-	-	-
iii) Un-Allocable Income	-	-	-	-
<b>TOTAL PROFIT /(-LOSS) BEFORE TAX</b>	<b>470.12</b>	<b>383.01</b>	<b>-86.12</b>	<b>1,364.94</b>

Place:Hyderabad  
Date:09.08.2021

for Jeevan Scientific Technology Limited  
On behalf of the Board of Directors  
*[Signature]*  
K. Krishna Kishore  
Vice Chairman & Managing Director

M Srikanth Sasidhar  
CFO

